Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Gacyclidine (Beaufour-Ipsen).

A P Mitha¹, K I Maynard

¹University of Alberta, Edmonton, Canada.

Current Opinion in Investigational Drugs (London, England : 2000)

|September 27, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Does Increasing Packing Density Using Larger Caliber Coils Improve Angiographic Results of Embolization of Intracranial Aneurysms at 1 Year: A Randomized Trial.

AJNR. American journal of neuroradiology·2020

Same author

Temporal resolution of dynamic angiography using flat panel volume CT: in vivo evaluation of time-dependent vascular pathologies.

AJNR. American journal of neuroradiology·2011

Same author

Avoiding stroke during cerebral arterial occlusion by temporarily blocking neuronal functions in the rabbit.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007

Same author

Tumefactive demyelinating lesions.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2007

Same author

Ossification of the posterior longitudinal ligament.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2003

Same author

Delayed multidose treatment with nicotinamide extends the degree and duration of neuroprotection by reducing infarction and improving behavioral scores up to two weeks following transient focal cerebral ischemia in Wistar rats.

Annals of the New York Academy of Sciences·2001

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Gacyclidine (GK-11) shows potential for traumatic brain injury treatment, with Phase II trials completed. Development for acute spinal cord injury was discontinued due to disappointing results.

Area of Science:

Neuroscience
Pharmacology
Clinical Trials

Background:

Beaufour-Ipsen is investigating gacyclidine (GK-11) as a therapeutic agent.
Traumatic brain injury (TBI) and acute spinal cord injury (SCI) are significant neurological conditions.

Purpose of the Study:

To evaluate the efficacy and safety of gacyclidine for TBI treatment.
To assess the potential of gacyclidine in managing acute spinal cord injury.

Main Methods:

Phase II clinical trials were conducted for both TBI and SCI indications.
Data from completed Phase II trials were analyzed to determine treatment outcomes.

Main Results:

Phase II trials for TBI were completed by October 1999, with further development contingent on partnership.

Related Experiment Videos

Phase II trials for acute SCI yielded disappointing results, leading to discontinuation of development for this indication.

Conclusions:

Gacyclidine (GK-11) presents a potential therapeutic option for traumatic brain injury.
Further clinical development of gacyclidine for acute spinal cord injury has been ceased.